ENGN — enGene Holdings Inc.
$1.56-1.27%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for ENGN in the TickerWise workspace.
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: CA
- Exchange: NASDAQ Capital Market
- Employees: 56
- Website: https://www.engene.com
Latest SEC filings for ENGN
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.